Global Hereditary Angioedema Market: Size, Trends & Forecasts (2017-2021)
Scope of the Report
The report entitled “Global Hereditary Angioedema Market: Size, Trends & Forecasts (2017-2021)” provides a detailed analysis of the global hereditary market with analysis of market size by value, growth, segments, etc.
The report also includes a detailed regional analysis of the US and Europe hereditary angioedema market comprising of hereditary market by value, segments and growth. Under competitive landscape different products in the global hereditary angioedema market have been compared on basis of various technical parameters.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global hereditary angioedema market has also been forecasted for the years 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Shire Plc, iBio, Inc., Pharming Group NV and CSL Limited are some of the key players operating in the global hereditary angioedema market whose company profiling is done in the report. In this segment of the report, business overview, financial overview and the business strategies of the companies are provided.
Pharming Group NV
Angioedema can be defined as a disorder in which there is a rapid inflammation of the dermis, subcutaneous tissue, mucosa (cavities surrounding internal organs) and sub mucosal tissues. Angioedema can further be divided into acquired and hereditary angioedema. Acquired angioedema is generally caused due to allergy. On the other hand, hereditary angioedema is caused due to genetic mutation.
Hereditary angioedema (HAE) is defined as a condition highlighted by frequent incidences of severe swelling. It is a rarely inherited disorder. It most commonly affects limbs, face, intestinal and respiratory tract and causes severe swelling in these parts of the body. Low levels of C1 inhibitor, a protein leads to the over activation of bradykinin. Bradykinin is a chemical which is the prime cause the occurrence of angioedema.
The global hereditary angioedema market is projected to increase at a healthy rate during the forecasted period (2017-2021). This growth is expected on account of many growth drivers such as increased diagnosis in the US and Europe, advantages of preventive therapy, approval of Berinert for pediatric treatment, launch of Haegarda C1 inhibitor and some other major products in the pipeline.
However, the market also faces certain challenges such as high prophylaxis cost, side effects of Cinryze and long term prophylactic treatment. Oral therapy for hereditary angioedema attacks and SHP643 monoclonal antibody are some of the trends in the global hereditary angioedema market.